Title: Treating Intracerebral Hemorrhage in the Anti-coagulated Patient
1Treating Intracerebral Hemorrhage in the
Anti-coagulated Patient
2Edward P. Sloan, MD, MPHProfessorDepartment
of Emergency MedicineUniversity of Illinois
College of MedicineChicago, IL
3Attending PhysicianEmergency
MedicineUniversity of Illinois HospitalOur
Lady of the Resurrection HospitalChicago, IL
4Andrew Asimos, MDDirector of Emergency Stroke
CareNeuroscience and Spine InstituteCarolinas
Medical Center, Charlotte, NCAdjunct Associate
Professor, Department of Emergency
MedicineUniversity of North Carolina School of
Medicine at Chapel Hill
5Attending PhysicianEmergency MedicineCarolinas
Medical CenterDepartment of Emergency
MedicineCharlotte, NC
6CME Disclosure Statement
- Member of an EM advisory panel for Novo Nordisk
- Will be discussing off-label use for rFVIIa
7Session Objectives
- Present a relevant patient case
- State key clinical questions
- Outline the procedure and therapeutic options for
treating ICH related to anticoagulation
8A Clinical Case
9Clinical History
- 66 year old male presents with acute onset of
aphasia and right sided weakness while eating at
home - Initially complained of a headache
- BP of 220/118 mm Hg
- Accucheck 316
- Initial GCS of 14
10Paramedics Report
- Patient less responsive than initially
- Aphasia and weakness worsening?
- He is on a bag o meds
- Per family, started an antibiotic a week ago
11ED Presentation
- ED VS
- BP 224/124, P 100, RR 16, T 98.8, pulse ox 99
- Somnolent, but slowly responds to simple commands
- Snores a bit when not stimulated
- Clear lungs and a regular cardiac rate and rhythm
- Neurological screening exam
- Pupils midpoint, equal and reactive
- L sided gaze preference
- R facial weakness
- R upper gt lower extremity weakness
- Expressive aphasia
12Key Clinical Questions
- What are the key diagnostic issues?
- What are the potential complicating factors?
- What guidelines direct potential therapies?
- What is the urgency of potential interventions?
- What is the relative availability of those
therapies in our institution?
13Bag o Meds
14The Great American Poison
15Which of these belong to this patient?
16Oral Anticoagulant (OAC) Related ICH Key
Clinical Concepts
17OAC Related ICH
- OAC use increases ICH risk 7-10x
- gt10 fold risk if over 50 years of age
- Increased risk dramatic if INR gt4.0
- 50-90 OAC-related ICHs with target INR
- ICH risk greatest at the start of treatment
Punthakee X et al. Thrombosis Research
200310831-36. Butler AC. Tate RC. Blood Reviews
19981235-44 Winzen AR et al. Ann Neurol
198416553-8. Franke CL et al. Stroke
199021726-30. Hylek EM. Singer DE. Ann Int Med
1994120(11)897-902.
18Factors Predicting Worse Outcome in ICH
- Hematoma Volume
- At least 40 of all ICH patients experience early
hemorrhage growth of gt 33 of baseline volume
within 24 hours - Depressed Level of Consciousness
Hart RG. Neurology 200055907-908. Brott T et
al. Stroke 1997281-5.
19Early ICH Growth
2 hours after onset
6.5 hours after onset
20OAC-Related ICH
- More frequent progression of bleeding
- More protracted bleeding
- Larger hematomas
- Higher mortality
- Hematoma volume correlates with mortality
- Hematoma volume may be minimized with prompt
correction of coagulation
Freeman WD et al. Mayo Clin Proc
200479(12)1495-1500. Butler AC. Tate RC. Blood
Reviews 19981235-44. Flibotte JJ et al.
Neurology 2004631059-1064.
21Warfarin-Related ICH Risk Factors
- Advanced Age
- Hypertension
- Intensity of Anticoagulation
- Cerebral amyloid angiopathy
Hart RG. Neurology 200055907-908.
22Effect of Warfarin on Outcome of ICHOutcome at
3 months
Rosand J et al. Arch Intern Med 2004164880-884.
23Warfarin
- Achieves its anticoagulant effect by reducing
activity of vitamin K dependent cofactors II,
VII, IX, and X - Considerable drug interactions
24Evidence Based Intracerebral Hemorrhage Patient
Treatments
Broderick JP et al. Stroke 199930905-15.
25AHA ICH Treatment Guidelines
- AHA Stroke Council 1999 Stroke
- Key Concept General ICH guidelines exist
- Detailed data on disease, epidemiology, BP
management, ICP Rx recommendations - Lack any recommendations regarding ICH in the
setting of anticoagulation - Almost seven years without revision
Broderick JP et al. Stroke 199930905-15.
26Sixth ACCP Recommendations on Managing Patients
with high INR Values
Chest 2001119(1 Suppl)22S-38S
27Sixth ACCP Recommendations on Managing Patients
with high INR Values
- Consensus, evidence based
- 2001 Chest
- Key Concept Guidelines exist for managing
anticoagulated patients with serious or life
threatening bleeding - Grade 2C evidence
Chest 2001119(1 Suppl)22S-38S
28OAC ICH Rx Driving Principles
- Measure INR
- Establish the extent of INR elevation
(lt 5, 5-9, gt9) and presence of bleeding - Determine if an immediate neurosurgical
intervention is needed - Administer Vitamin K IV
- Order Coagulation Factor Replacement
29ACCP Guidelines for Warfarin-related Elevated
Anti-coagulation
Derived from Chest 2001119(1 Suppl)22S-38S,
courtesy of Wjasow C, McNamara R. J Emerg Med
200324(2)169-72.
30Elevated INR Therapy The Procedure
31INR
- Based on the Prothrombin time test
- Sensitive to reductions of Vitamin-K dependent
clotting factors II, VII, and X - Not factor IX
- Designed specifically for stably anticoagulated
patients - May be inappropriate test following replacement
therapy with either plasma or clotting factor
concentrates
32Elevated INR Rx Procedure
- Vitamin K 10 mg by slow IV infusion
33Vitamin K
- Necessary to achieve more than a temporary
reversal of anticoagulation - Adequate response requires at least 2-6 and up to
24 hours - Anaphylactic or anaphylactoid reactions rarely
associated with IV administration - Safest and most rapidly acting route of
administration unclear
Wjasow C, McNamara R. J Emerg Med
200324(2)169-72. Fiore LD et al. J Thrombosis
Thrombolysis 200111(2)175-83.
34Coagulation Factor Replacement
- Options include
- FFP
- Prothrombin Complex Concentrates (PCC)
- Recombinant Factor VIIa
- Normal coagulation achieved more rapidly with
PCC, rFVIIa than with FFP
Fredriksson K et al. Stroke 199223972-977. Makri
s M et al. Thromb Haemostasis 199777477-480.
35Bedside RealitiesCan you answer these process
questions?
- Is thawed FFP immediately available from your
blood bank? - How long will it take your blood bank to get it
to you? - Does your hospital blood bank or inpatient
pharmacy store PCC and rFVIIa? - What is the relative rapidity of response of each
of these agents?
36Elevated INR Rx Procedure
- Vitamin K 10 mg by slow IV infusion
- Fresh frozen plasma (5-8 ml/kg, 1-2 units,
250-500 cc total)
37Elevated INR Rx Procedure
- Vitamin K 10 mg by slow IV infusion
- Fresh frozen plasma (5-8 ml/kg, 1-2 units,
250-500 cc total) - Prothrombin Complex Concentrate 25-50 IU/kg
- Dose based on Factor IX units
- Alternatively, 500 IU initially followed by
second administration of 500 IU according to the
INR value measured just after the first
administration
OR
38Elevated INR Rx Procedure
- Vitamin K 10 mg subq or IVP
- Fresh frozen plasma (5-8 ml/kg)
- 1-2 units, 250-500 cc total
- Prothrombin Complex Concentrate 25-50 IU/kg
- Recombinant Factor VIIa (40-60 µgr/kg)
- Usually 3-4 mg total
OR
OR
39Drawbacks to FFP Reversing OAC
- Time-consuming?
- Can delay neurosurgical evacuation
- May require clinically substantial IV fluid
volumes - Contains a variable content of Vitamin
K-dependent clotting factors - May not completely correct INR
- May not adequately correct for factor IX
- Risk of viral transmission
- Not pooled
- HIV 11,900,000
- Hepatitis C 11,000,000
- Hepatitis B 1137,000
Makris M et al. Thromb Haemostasis
199777477-480.
40PCC
- Prepared from pooled plasma of thousands of blood
donors - Less viral transmission risk than FFP
- Contains vitamin K-dependent procoagulant and
factors - Infused over 15 minutes
- Relative thromboembolic risk unclear
- Acquisition cost of usual adult dose 450
Abe et al. Rinsho to Kenkyu in Japanese
1987641327-37. Sorensen B et al. Blood
Coagulation and Fibrinolysis 200314469-477.
41Onset of Action of PCC
PCC dose7-27 IU/kg, Vit K dose 10 mg
Yasaka M et al. Thrombosis Research
200310825-30.
42Recombinant Factor VIIa
- Rapid onset of action
- Almost immediate
- Clinically apparent hemostasis in 10 minutes
- Short half life (2.3 hours)
- Relatively high acquisition cost
- 2,500-3,500 for 3-4 gm dose
Park p et al. Neurosurgery 20035334-39. Sorensen
B et al. Blood Coagulation and Fibrinolysis
200314469-477. Novoseven package insert.
Princeton, NJ Novo Nordisk Pharmaceuticals, Inc
2003.
43(No Transcript)
44Recombinant Factor VIIa
- Up to 7 risk of thromboembolic events
- AMI
- PE
- Cerebral infarction
- DIC
- Demonstrated OAC efficacy in case series
- Phase IIB trial demonstrates effectiveness
Park P et al. Neurosurgery 20035334-39. Mayer
SA et al. N Eng J Med 2005352777-85. Sorensen B
et al. Blood Coagulation and Fibrinolysis
200314469-477. Freeman WD et al. Mayo Clin Proc
200479(12)1495-1500.
45INR Following Recombinant Factor VIIa
Administration
Freeman WD et al. Mayo Clin Proc
200479(12)1495-1500.
46ED Treatment and Patient Outcome
47ED Patient Management
- The BP treated with IV labetalol
- The INR was noted to be 5.6
- Vitamin K administered
- 2 units FFP administered
- Pt admitted to the neurosurgical ICU
48Patient Outcome
- The hemorrhage size increased slightly on CT with
slight intraventricular extension - The patients clinical condition slightly
improved gradually - Discharged to rehab 10 days after admission
49ED ICH Patient RxA Retrospective
50OAC Related ICH
- Know the treatment guidelines
- Know the relative availability at your
institution of different coagulation factor
replacements - Communicate with neurosurgical consultants
regarding a potential indication for PCC or
rFVIIa use
51Thank you!! www.ferne.orgferne_at_ferne.orgEdwar
d P. Sloan, MD, MPHedsloan_at_uic.edu312 413 7490
ferne_2005_acep_sa_sloan_ICH_antiocoag_fshow.ppt
9/9/2005 827 AM